Comparing therapeutic efficacy of N-acetyl cysteine with the combination of N-acetyl cysteine and Cimetidine in acute acetaminophen toxicity

Determination of therapeutic efficacy of N-acetyl cysteine with the combination of N-acetyl cysteine and Cimetidine in acute acetaminophen toxicity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013102915204N1

Enrollment

Registered

2014-01-01

Start date

2013-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute acetaminophen toxicity. Poisoning by drugs, medicaments and biological substances

Interventions

Intervention 1: Control group: N-acetyl cysteine patients are treated (based on the risk assessment nomogram of acetaminophen serum level). Intervention 2: Intervention group: the combination of

Treatment - Drugs

Control group: N-acetyl cysteine patients are treated (based on the risk assessment nomogram of acetaminophen serum level)

Intervention group: the combination of N-acetyl cysteine and Cimetidine patients are treated (based on the risk assessment nomogram of acetaminophen serum level). Cimetidine dose: 300 milligr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion major criteria to study, are: having para-clinical acetaminophen toxicity (toxic acetaminophen serum levels), and referring to the emergency poisoning department of Imam Reza Hospital, less than 8 hours from the poisoning. Exclusion major criteria from study, are as follows: having multiple toxicities; simultaneous diseases affecting the liver enzymes (e.g. heart failure, congenital liver defects, and hepatitis); recent (less than a week) or regular consumption of other drugs;Those patients who didn’t consent to the treatment, or were discharged from the hospital, were also excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum level of acetaminophen. Timepoint: admission-next morning- discharging. Method of measurement: blood Sampling.	—

Secondary

Measure	Time frame
Serum level of Serum aminotransferases. Timepoint: admission-next morning- discharging. Method of measurement: blood Sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhad Bagherian

Mashhad University of Medical Sciences

dr_f_bagherian@yahoo.com+98 51 1841 8890

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026